Home
 /
Papers
 /
Evolutionary Biology
 /
Predicting the antigenic evolution of seasonal influenza viruses using phylogenetic convergence
Preprint
Open access
V1
Top 1% · Validated by QED

Predicting the antigenic evolution of seasonal influenza viruses using phylogenetic convergence

Samuel A. Turner, David J. Pattinson, Ron A. M. Fouchier +1 more
April 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.04.10.717627
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Evolutionary Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that convergent evolution pinpoints the specific hemagglutinin substitutions driving antigenic change more than a year before they spread, this work transforms influenza vaccine strain selection from reactive surveillance into genuine forward-looking prediction.

QED claims analysis

Summary

Measuring convergent evolution in global H3N2 influenza phylogenies through log convergence ratios prospectively identifies amino acid substitutions that cause major antigenic changes, with cluster transition substitutions nearly always ranking among the top few positively selected substitutions at key antigenic positions more than one year before the new antigenic cluster becomes established, enabling earlier vaccine strain selection.

See full analysis
Main Claim 1 –

LCR Infers Selection on Amino-Acid Substitutions from Convergence

Supporting evidence

  • Trunk and Major-Branch Substitutions Show Positive Selection by LCR
Main Claim 2 –

Antigenic-Shift Substitutions Rank Among Top Positively Selected LCRs

Supporting evidence

  • LCR Outperforms Clade Size for Predicting Cluster-Transition Substitutions
  • Mutation-Rate Biases Shape Which Substitutions Drive Antigenic Evolution
  • High-LCR Nontransition Substitutions Often Become Future Evolutionary Pathways
Main Claim 3 –

Convergence Signals Predict Cluster-Transition Substitutions Over One Year Early

Supporting evidence

  • Early Transition-Substitution Occurrences Are True Convergence, Not Misplacement
Main Claim 4 –

LCR Flagged N158K and K189R Before Their DA21 Rise

Abstract

The antigenic evolution of human seasonal influenza viruses is primarily driven by single amino acid substitutions immediately adjacent to the receptor binding site in the hemagglutinin (HA) protein. The ability to predict these substitutions would allow vaccine strains to be selected with an understanding of likely future antigenic variation. Here, we estimate the effect of HA substitutions on viral fitness using measurements of convergent evolution in a large phylogeny. We show that the substitutions which have historically caused major antigenic changes in H3N2 influenza viruses were nearly always one of few substitutions near the HA receptor binding site estimated to be under positive selection in sequences collected before the antigenic transition, based on convergent acquisition of the substitution in multiple independent lineages. Furthermore, this signal predates the establishment of the major clade containing the antigenic substitution by more than one year, so is highly informative for prospective prediction.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?